Novo Nordisk A/S Common Stock (NVO)

R&D Expenses

kr 17.79B

Quarterly · Period ending: · DKK

NVO logo

NVO R&D Expenses

Latest reportedkr 17.79B DKK
NVO Quarterly R&D Expenses · DKK (kr 0.00 → kr 17.79B)
High-resolution chart · PNG

NVO r&d expenses history

Quarterly · DKK. Dates are reporting period ends; fiscal years can differ from calendar years.

Novo Nordisk A/S Common Stock R&D Expenses — Quarterly (DKK)
Period endingR&D Expenses (DKK)
17,787,000,000
10,284,000,000
14,648,000,000
15,393,000,000
11,690,000,000
10,308,000,000
13,802,000,000
9,488,000,000
16,166,000,000
8,606,000,000
10,460,000,000
8,128,000,000
7,127,000,000
6,728,000,000
8,085,000,000
5,633,000,000
5,123,000,000
5,206,000,000
5,632,000,000
4,252,000,000
3,944,000,000
3,944,000,000
4,483,000,000
3,911,000,000
3,291,000,000
3,777,000,000
4,384,000,000
3,601,000,000
3,557,000,000
2,678,000,000
4,544,000,000
3,644,000,000
3,296,000,000
3,321,000,000
3,983,000,000
3,328,000,000
3,414,000,000
3,289,000,000
4,470,000,000
3,458,000,000
3,331,000,000
3,304,000,000
4,034,000,000
3,289,000,000
3,035,000,000
3,250,000,000
3,865,000,000
3,654,000,000
3,075,000,000
3,168,000,000
3,566,000,000
2,795,000,000
2,715,000,000
2,657,000,000
3,210,000,000
2,617,000,000
2,563,000,000
2,507,000,000
2,752,000,000
2,263,000,000
2,323,000,000
2,290,000,000
2,735,000,000
2,302,000,000
2,434,000,000
2,131,000,000
2,387,000,000
1,884,000,000
1,849,000,000
1,744,000,000
2,462,175,000
1,579,000,000
1,981,027,000
1,858,000,000
3,426,746,900
1,723,623,000
1,754,771,000
1,646,389,000
1,911,745,000
1,488,149,000
1,500,263,000
1,422,071,000
1,545,140,000
1,228,214,000
1,193,963,000
1,109,231,000
1,296,815,000
1,083,175,000
981,052,000
1,027,138,000
1,165,559,000
1,051,009,000
1,000,888,000
972,005,000
0
0
0
0
0
0
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.